The Henrietta Lacks Case: Ongoing Litigation Seeks Closure

Abstract

The litigation brought by the Estate of Henrietta Lacks against Thermo Fisher Scientific, Ultragenyx Pharmaceutical, and Novartis Pharmaceuticals reframes benefit-sharing from voluntary institutional ethics into an enforceable legal duty. By pleading a single equitable claim - unjust enrichment - the Estate seeks to bypass the property and informed-consent doctrines that have defeated comparable tissue-appropriation suits, while accepting distinctive risks involving remoteness, limitations, causation, and apportionment. This commentary examines the strategy's strengths and vulnerabilities through the still-pending Ultragenyx case, and considers its implications for research consent, prospective benefit-sharing frameworks, and bioethics pedagogy. Whether or not the remaining claim succeeds, the litigation has already altered the conversation about who should profit from human biological materials.